During the last session, Zomedica Corp (AMEX:ZOM)’s traded shares were 3.47 million, with the beta value of the company hitting 1.03. At the end of the trading day, the stock’s price was $0.12, reflecting an intraday loss of -1.50% or -$0.01. The company’s market capitalization is $121.91M, and the average intraday trading volume over the past 10 days was 4.95 million shares, and the average trade volume was 6.75 million shares over the past three months.
Zomedica Corp (ZOM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ZOM has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.01.
Zomedica Corp (AMEX:ZOM) trade information
Zomedica Corp (ZOM) registered a -1.50% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.50% in intraday trading to $0.12, hitting a weekly high. The stock’s 5-day price performance is -4.31%, and it has moved by 3.67% in 30 days. Based on these gigs, the overall price performance for the year is -5.18%. The short interest in Zomedica Corp (AMEX:ZOM) is 51.14 million shares and it means that shorts have 17.24 day(s) to cover.
Zomedica Corp (ZOM) estimates and forecasts
Statistics show that Zomedica Corp has underperformed its competitors in share price, compared to the industry in which it operates. Zomedica Corp (ZOM) shares have gone down -17.07% during the last six months, with a year-to-date growth rate less than the industry average at -150.00% against 14.80.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.1M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 7.78M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 27.70%. While earnings are projected to return -37.14% in 2025.
ZOM Dividends
Zomedica Corp is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zomedica Corp (AMEX:ZOM)’s Major holders
Zomedica Corp insiders own 1.78% of total outstanding shares while institutional holders control 8.33%, with the float percentage being 8.48%. VANGUARD GROUP INC is the largest shareholder of the company, while 101.0 institutions own stock in it. As of 2024-06-30, the company held over 29.93 million shares (or 3.054% of all shares), a total value of $382.18 million in shares.
The next largest institutional holding, with 26.21 million shares, is of BLACKROCK INC.’s that is approximately 2.6742% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $334.65 million.
Also, the Mutual Funds coming in first place with the largest holdings of Zomedica Corp (ZOM) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 33.16 shares. This amounts to just over 3.38 percent of the company’s overall shares, with a $4.12 million market value. The same data shows that the other fund manager holds slightly less at 13.41, or about 1.37% of the stock, which is worth about $1.67 million.
